Reuters logo
BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer
2017年8月23日 / 下午1点26分 / 1 个月前

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

Aug 23 (Reuters) - Celldex Therapeutics Inc

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex Therapeutics Inc - ‍topline data likely in Q2 of 2018 for phase 2b study of Glembatumumab Vedotin​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below